Most readers would already be aware that Boston Scientific's (NYSE:BSX) stock increased significantly by 16% over ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) ...

With a market cap of $154.3 billion, Boston Scientific Corporation (BSX) is a global developer, manufacturer, and marketer of ...

Boston Scientific stock has gained 57% in 2024 but the average analyst price target sits at 101.06, according to FactSet. That represents a further 11% upside for BSX as it looks to forge a new ...

When assessing Boston Scientific’s valuation against the S&P 500, the stock presents as notably expensive across key metrics. The company’s price-to-sales (P/S) ratio stands at 8.3 ...

Boston Scientific’s revenue climbed 32%, rising from $12.7 billion in 2022 to $16.7 billion in 2024, driven by an increase in total procedures and the introduction of new products such as POLARx ...

New Strategic Investments to Drive Electrophysiology: Following the acquisitions of Farapulse and Baylis Medical in 2022, Boston Scientific’s EP business is rapidly growing in market share globally.

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth expected in the next year. Learn more on BSX stock here.